HC Wainwright Has Pessimistic View of REGENXBIO Q3 Earnings

Key Points

• HC Wainwright sharply cut its Q3 2026 EPS forecast for REGENXBIO to $(1.20) from $0.32, while maintaining a Buy rating and $23 price target.
• REGENXBIO’s latest quarter beat expectations, reporting $0.43 EPS versus $0.08 expected and revenue of $108.02 million versus $97.63 million anticipated, though profitability metrics remained deeply negative.
• Analyst sentiment is mixed but leans positive: the stock carries a “Moderate Buy” consensus rating with a $23.73 average price target, while shares recently opened at $10.65.

REGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share (EPS) estimates for REGENXBIO in a research report issued to clients and investors on Monday, August 10th. HC Wainwright analyst Y. Chen now forecasts that the biotechnology company will post earnings per share of ($1.20) for the quarter, down from their previous forecast of $0.32. HC Wainwright currently has a "Buy" rating and a $23.00 target price on the stock. The consensus estimate for REGENXBIO's current full-year earnings is ($3.95) per share. HC Wainwright also issued estimates for REGENXBIO's Q4 2026 earnings at ($1.09) EPS, FY2026 earnings at ($3.65) EPS, Q1 2027 earnings at ($1.09) EPS, Q4 2027 earnings at ($0.94) EPS and FY2027 earnings at ($4.02) EPS.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.08 by $0.35. The business had revenue of $108.02 million for the quarter, compared to analysts' expectations of $97.63 million. REGENXBIO had a negative return on equity of 220.07% and a negative net margin of 112.58%.

A number of other analysts also recently weighed in on RGNX. Barclays downgraded shares of REGENXBIO from an "overweight" rating to a "hold" rating in a research report on Friday. Morgan Stanley reissued an "overweight" rating and issued a $18.00 target price on shares of REGENXBIO in a research report on Friday. Weiss Ratings restated a "sell (e+)" rating on shares of REGENXBIO in a research note on Monday, June 8th. Leerink Partners raised their price objective on REGENXBIO from $17.00 to $18.00 and gave the stock an "outperform" rating in a research note on Monday, June 22nd. Finally, Robert W. Baird lifted their price objective on shares of REGENXBIO from $27.00 to $32.00 and gave the stock an "outperform" rating in a report on Monday, June 22nd. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $23.73.

REGENXBIO Stock Up 2.2%

RGNX stock opened at $10.65 on Wednesday. REGENXBIO has a 52-week low of $5.45 and a 52-week high of $16.19. The stock's 50 day moving average is $10.17 and its two-hundred day moving average is $9.34. The company has a market capitalization of $550.61 million, a PE ratio of -2.81 and a beta of 0.94.

Insider Transactions at REGENXBIO

In related news, insider Steve Pakola sold 36,725 shares of the company's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $12.86, for a total transaction of $472,283.50. Following the completion of the transaction, the insider directly owned 213,009 shares in the company, valued at $2,739,295.74. This represents a 14.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last ninety days, insiders sold 58,494 shares of company stock worth $718,232. Insiders own 14.22% of the company's stock.

Hedge Funds Weigh In On REGENXBIO

Several institutional investors have recently modified their holdings of the company. Versant Capital Management Inc lifted its position in REGENXBIO by 60.4% in the 2nd quarter. Versant Capital Management Inc now owns 2,741 shares of the biotechnology company's stock valued at $33,000 after purchasing an additional 1,032 shares during the last quarter. Aquatic Capital Management LLC acquired a new position in REGENXBIO during the 3rd quarter valued at about $37,000. Captrust Financial Advisors bought a new position in REGENXBIO in the 2nd quarter worth about $85,000. Entropy Technologies LP bought a new position in REGENXBIO in the 1st quarter worth about $87,000. Finally, Prudential Financial Inc. acquired a new stake in shares of REGENXBIO in the second quarter valued at approximately $87,000. Institutional investors own 88.08% of the company's stock.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO's pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source